Literature DB >> 7698703

Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha.

J C Booth1, G R Foster, U Kumar, R Galassini, R D Goldin, J L Brown, H C Thomas.   

Abstract

The effects of hepatitis C virus genotype and viraemia on disease outcome in patients with chronic hepatitis C virus infection were studied. Patients infected with genotype 1 tended to develop more severe disease, and to respond less well to interferon (IFN) treatment, but no pretreatment variable successfully predicted either the severity of the disease or the response to IFN. Failure to eliminate the virus during the first three months of therapy, however, predicted a failure to derive long term benefit from the current IFN regime. Hence pretreatment variables cannot be used to determine whether individual patients will respond to IFN, but observations during the first three months of therapy can be used to decide which patients will not respond to prolonged therapy. In these patients consideration should be given to changing the IFN dosing regime or using alternative treatments.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7698703      PMCID: PMC1382459          DOI: 10.1136/gut.36.3.427

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  34 in total

1.  Hepatitis C serotype and response to interferon therapy.

Authors:  L Chemello; A Alberti; K Rose; P Simmonds
Journal:  N Engl J Med       Date:  1994-01-13       Impact factor: 91.245

2.  Serum HCV RNA levels in chronic HCV hepatitis measured by quantitative PCR assay; correlation with serum AST.

Authors:  U Kumar; H C Thomas; J Monjardino
Journal:  J Virol Methods       Date:  1994-04       Impact factor: 2.014

3.  Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease.

Authors:  G Dusheiko; H Schmilovitz-Weiss; D Brown; F McOmish; P L Yap; S Sherlock; N McIntyre; P Simmonds
Journal:  Hepatology       Date:  1994-01       Impact factor: 17.425

4.  Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity.

Authors:  P Simmonds; F McOmish; P L Yap; S W Chan; C K Lin; G Dusheiko; A A Saeed; E C Holmes
Journal:  J Gen Virol       Date:  1993-04       Impact factor: 3.891

5.  Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis.

Authors:  M R Jacyna; M G Brooks; R H Loke; J Main; I M Murray-Lyon; H C Thomas
Journal:  BMJ       Date:  1989-01-14

Review 6.  Sequence variability of hepatitis C virus and its clinical relevance.

Authors:  G Dusheiko; P Simmonds
Journal:  J Viral Hepat       Date:  1994       Impact factor: 3.728

7.  Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities.

Authors:  F McOmish; S W Chan; B C Dow; J Gillon; W D Frame; R J Crawford; P L Yap; E A Follett; P Simmonds
Journal:  Transfusion       Date:  1993-01       Impact factor: 3.157

8.  Long-term follow-up of acute and chronic non-A, non-B post-transfusion hepatitis: evidence of progression to liver cirrhosis.

Authors:  G Realdi; A Alberti; M Rugge; A M Rigoli; F Tremolada; L Schivazappa; A Ruol
Journal:  Gut       Date:  1982-04       Impact factor: 23.059

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

10.  Quantitation and typing of serum hepatitis C virus RNA in patients with chronic hepatitis C treated with interferon-beta.

Authors:  Y Kobayashi; S Watanabe; M Konishi; M Yokoi; R Kakehashi; M Kaito; M Kondo; Y Hayashi; T Jomori; S Suzuki
Journal:  Hepatology       Date:  1993-12       Impact factor: 17.425

View more
  12 in total

1.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

Review 2.  [Therapy of hepatitis C].

Authors:  D M Alscher; J C Bode
Journal:  Med Klin (Munich)       Date:  1997-03-15

3.  Adding interventions to interferon in chronic HCV infections.

Authors:  J Main
Journal:  Gut       Date:  1996-11       Impact factor: 23.059

4.  Clinical relevance of hepatitis C virus genotypes.

Authors:  P Simmonds
Journal:  Gut       Date:  1997-03       Impact factor: 23.059

5.  Duration of HCV infection as a predictor of nonresponse to interferon.

Authors:  A Craxì; V Di Marco; C Cammà; P Almasio; S Magrin
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

6.  Predictors of response to interferon therapy.

Authors:  G Saracco; M Rizzetto
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

7.  The management of chronic hepatitis C virus infection.

Authors:  J C Booth; J L Brown; H C Thomas
Journal:  Gut       Date:  1995-10       Impact factor: 23.059

Review 8.  Pathophysiology and treatment of hepatitis C.

Authors:  H C Thomas; J Booth; J Brown
Journal:  Drugs       Date:  1996       Impact factor: 9.546

9.  Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.

Authors:  S D Ryder; W L Irving; D A Jones; K R Neal; J C Underwood
Journal:  Gut       Date:  2004-03       Impact factor: 23.059

10.  Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.

Authors:  Javier Moreno; Gloria Moraleda; Rafael Barcena; Mluisa Mateos; Santos del Campo
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.